Table 2 Pooled efficacy of endostatin combined with radiotherapy or chemoradiotherapy
Endpoints | Group | No. of studies | No. of cases | Weighted pooled data (95%CI) |
|---|---|---|---|---|
Response rate | ||||
ORR (%) | Overall | 7 | 271 | 77.2 (71.8–81.8) |
ECRT | 4 | 212 | 77.5 (71.4–82.7) | |
ERT | 3 | 59 | 76.1 (63.5–85.3) | |
1-yr LCR (%) | Overall | 2 | 73 | 76.1 (65.0–84.0) |
2-yr LCR (%) | Overall | 2 | 73 | 65.8 (54.3–75.8) |
Progression-free survival | ||||
Median PFS (months) | Overall | 6 | 246 | 11.3 |
ECRT | 4 | 212 | 11.2 | |
ERT | 2 | 34 | 11.8 | |
1-yr PFS rate (%) | ECRT | 2 | 115 | 49.6 (40.5–58.6) |
2-yr PFS rate (%) | ECRT | 2 | 115 | 31.7 (23.8–40.8) |
3-yr PFS rate (%) | ECRT | 2 | 115 | 23.7 (16.7–32.5) |
Overall survival | ||||
Median OS (months) | Overall | 4 | 142 | 18.9 (15.3–22.5) |
ECRT | 2 | 97 | 18.4 (9.7–27.0) | |
ERT | 2 | 45 | 19.6 (16.2–23.1) | |
1-yr OS rate (%) | Overall | 4 | 154 | 79.4 (72.1–85.1) |
ECRT | 2 | 115 | 81.6 (73.5–87.7) | |
ERT | 2 | 39 | 72.8 (55.9–85.0) | |
2-yr OS rate (%) | Overall | 3 | 140 | 59.0 (49.7–67.8) |
3-yr OS rate (%) | ECRT | 2 | 115 | 55.7 (45.6–65.6) |
ECRT | 2 | 115 | 43.9 (29.8–59.0) | |